PAHO-Gilead HIV prevention deal expands access in Latin America
AHF says a new agreement between Gilead Sciences and PAHO could expand access to lenacapavir for HIV prevention in 14 Latin American countries. The group said pricing, timelines and other key terms still need to be made transparent.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.